Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (12): 1302-1307.doi: 10.3969/j.issn.1000-6621.2021.12.013
• Original Articles • Previous Articles Next Articles
WANG Yi-ting*, ZHENG Hui-wen, ZHAO Bing, XIA Hui, WANG Sheng-fen, OU Xi-chao, ZHOU Yang, SONG Yuan-yuan, ZHENG Yang, ZHAO Yan-lin(), SHEN A-dong()
Received:
2021-08-23
Online:
2021-12-10
Published:
2021-12-01
Contact:
ZHAO Yan-lin,SHEN A-dong
E-mail:zhaoyl@chinacdc.cn;shenad18@126.com
WANG Yi-ting, ZHENG Hui-wen, ZHAO Bing, XIA Hui, WANG Sheng-fen, OU Xi-chao, ZHOU Yang, SONG Yuan-yuan, ZHENG Yang, ZHAO Yan-lin, SHEN A-dong. Preliminary study on clarithromycin resistance gene of Mycobacterium abscessus complex[J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1302-1307. doi: 10.3969/j.issn.1000-6621.2021.12.013
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.12.013
引物名称 | 引物序列(5'~3') |
---|---|
16S rRNA-F | AGAGTTTGATCMTGGCTCAG |
16S rRNA-R | CCGTCAATTCMTTTRAGTTT |
rpoB-F | GGCAAGGTCACCCCGAAGGG |
rpoB-R | AGCGGCTGCTGGGTGATCATC |
hsp65-F | ATCGCCAAGGAGATCGAGCT |
hsp65-R | AAGGTGCCGCGGATCTTGTT |
转录间隔区-F | AAGTCGTAACAAGGTARCCG |
转录间隔区-R | TCGCCAAGGCATCCACC |
erm(41)-F | GACCGGGGCCTTCTTCGTGAT |
erm(41)-R | GACTTCCCCGCACCGATTCC |
rrl-F | GTAGCGAAATTCCTTGTCGG |
rrl-R | TTCCCGCTTAGATGCTTTCAG |
rrs-F | ATGACGTCAAGTCATCATGCC |
rrs-R | AGGTGATCCAGCCGCACCTTC |
药品 | MIC范围(μg/ml) | 耐药菌株[株(耐药率,%)] | ||||
---|---|---|---|---|---|---|
敏感 | 中度 | 耐药 | 脓肿分枝杆菌(218株) | 马赛分枝杆菌(163株) | ||
阿米卡星 | ≤16 | 32 | ≥64 | 6(2.8) | 7(4.3) | |
克拉霉素 | ≤2 | 4 | ≥8 | 14(6.4) | 17(10.4) | |
阿奇霉素 | ≤16 | - | ≥32 | 33(15.1) | 21(12.9) | |
利奈唑胺 | ≤8 | 16 | ≥32 | 34(15.6) | 36(22.1) | |
替加环素 | ≤1 | 2~4 | ≥8 | 50(22.9) | 56(34.3) | |
头孢西丁 | ≤16 | 32~64 | ≥128 | 56(25.7) | 51(31.3) | |
加替沙星 | ≤1 | 2 | ≥4 | 99(45.4) | 102(62.6) | |
莫西沙星 | ≤1 | 2 | ≥4 | 120(55.0) | 108(66.3) | |
妥布霉素 | ≤2 | 4 | ≥8 | 135(61.9) | 148(90.8) | |
亚胺培南 | ≤4 | 8~16 | ≥32 | 181(83.0) | 126(77.3) | |
米诺环素 | ≤1 | 2~4 | ≥8 | 198(90.8) | 83(50.9) | |
利福布汀 | ≤0.5 | - | ≥1 | 212(97.2) | 154(94.5) | |
美罗培南 | ≤4 | 8~16 | ≥32 | 213(97.7) | 159(97.5) | |
左氧氟沙星 | ≤1 | 2 | ≥4 | 216(99.1) | 155(95.1) |
脓肿分枝 杆菌复合群 | 菌株数 | 培养 时间 | 克拉霉素[ MIC(μg/ml)] | 耐药[株(耐 药率,%)] | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.0625 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | ||||
脓肿分枝杆菌 | ||||||||||||||
erm(41)T28型 | 185 | 第3天 | 19 | 31 | 27 | 28 | 32 | 27 | 10 | 4 | 1 | 1 | 5 | 11(5.9) |
第7天 | 5 | 9 | 6 | 8 | 13 | 22 | 24 | 25 | 21 | 17 | 35 | 98(53.0) | ||
第14天 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 16 | 19 | 32 | 115 | 182(98.4) | ||
erm(41)C28型 | 33 | 第3天 | 10 | 9 | 6 | 2 | 3 | 0 | 0 | 1 | 0 | 0 | 2 | 3(9.1) |
第7天 | 8 | 10 | 7 | 1 | 3 | 0 | 1 | 1 | 0 | 1 | 1 | 3(9.1) | ||
第14天 | 6 | 7 | 7 | 4 | 3 | 3 | 0 | 0 | 1 | 0 | 2 | 3(9.1) | ||
马赛分枝杆菌 | 163 | 第3天 | 51 | 43 | 28 | 12 | 4 | 4 | 4 | 5 | 3 | 2 | 7 | 17(10.4) |
第7天 | 43 | 37 | 24 | 17 | 10 | 10 | 5 | 4 | 3 | 2 | 8 | 17(10.4) | ||
第14天 | 29 | 20 | 17 | 24 | 22 | 27 | 5 | 2 | 1 | 4 | 12 | 19(11.7) | ||
合计 | 381 | 第3天 | 80 | 83 | 61 | 42 | 39 | 31 | 14 | 31 | 4 | 3 | 14 | 31(8.1) |
第7天 | 56 | 56 | 37 | 26 | 26 | 32 | 30 | 30 | 24 | 20 | 44 | 118(31.0) | ||
第14天 | 35 | 27 | 24 | 29 | 26 | 30 | 6 | 5 | 21 | 49 | 129 | 204(53.5) |
[1] |
Ratnatunga CN, Lutzky VP, Kupz A, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front immunol, 2020, 11:303. doi: 10.3389/fimmu.2020.00303.
doi: 10.3389/fimmu.2020.00303 pmid: 32194556 |
[2] |
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4):367-416. doi: 10.1164/rccm.200604-571ST.
doi: 10.1164/rccm.200604-571ST URL |
[3] |
Nasiri MJ, Haeili M, Ghazi M, et al. New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. Front microbiol, 2017, 8:681. doi: 10.3389/fmicb.2017.00681.
doi: 10.3389/fmicb.2017.00681 URL |
[4] |
Richard M, Gutierrez AV, Kremer L. Dissecting erm(41)-Mediated Macrolide-Inducible Resistance in Mycobacterium abscessus. Antimicrob Agents Chemother, 2020, 64(2):e01879-19. doi: 10.1128/AAC.01879-19.
doi: 10.1128/AAC.01879-19 |
[5] |
Mougari F, Amarsy R, Veziris N, et al. Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother, 2016, 71(8):2208-2212. doi: 10.1093/jac/dkw130.
doi: 10.1093/jac/dkw130 pmid: 27147307 |
[6] |
Maurer FP, Ruegger V, Ritter C, et al. Acquisition of clarithromycin rithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). J Antimicrob Chemother, 2012, 67(11):2606-2611. doi: 10.1093/jac/dks279.
doi: 10.1093/jac/dks279 URL |
[7] |
Springer B, Bottger EC, Kirschner P, et al. Phylogeny of the Mycobacterium chelonae-like organism based on partial sequencing of the 16S rRNA gene and proposal of Mycobacterium mucogenicum sp. nov. Int J Syst Bacteriol, 1995, 45(2):262-267. doi: 10.1099/00207713-45-2-262.
doi: 10.1099/00207713-45-2-262 pmid: 7537060 |
[8] |
Bicmen C, Gunduz AT, Coskun M, et al. Molecular detection and identification of Mycobacterium tuberculosis complex and four clinically important nontuberculous mycobacterial species in smear-negative clinical samples by the genotype mycobacteria direct test. J Clin Microbiol, 2011, 49(8):2874-2878. doi: 10.1128/JCM.00612-11.
doi: 10.1128/JCM.00612-11 pmid: 21653780 |
[9] |
Kim H, Kim SH, Shim TS, et al. Differentiation of Mycobacterium species by analysis of the heat-shock protein 65 gene (hsp65). Int J Syst Evol Micr, 2005, 55(Pt 4):1649-1656. doi: 10.1099/ijs.0.63553-0.
doi: 10.1099/ijs.0.63553-0 URL |
[10] |
Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin rithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother, 2011, 55(2):775-781. doi: 10.1128/AAC.00861-10.
doi: 10.1128/AAC.00861-10 URL |
[11] |
Nessar R, Reyrat JM, Murray A, et al. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother, 2011, 66(8):1719-1724. doi: 10.1093/jac/dkr209.
doi: 10.1093/jac/dkr209 URL |
[12] | Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes. 3rd ed. CLSI Standard M24. Wayne: Clinical and Laboratory Standards Institute, 2018. |
[13] |
Choi GE, Min KN, Won CJ, et al. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. Antimicrob Agents Chemother, 2012, 56(7):3549-3555. doi: 10.1128/AAC.00685-12.
doi: 10.1128/AAC.00685-12 URL |
[14] |
Wallace RJ Jr, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother, 2002, 46(10):3164-3167. doi: 10.1128/AAC.46.10.3164-3167.2002.
doi: 10.1128/AAC.46.10.3164-3167.2002 URL |
[15] |
Li B, Yang S, Chu H, et al. Relationship between Antibiotic Susceptibility and Genotype in Mycobacterium abscessus Clinical Isolates. Front Microbiol, 2017, 8:1739. doi: 10.3389/fmicb.2017.01739.
doi: 10.3389/fmicb.2017.01739 URL |
[16] |
Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med, 2016, 195(6):814-823. doi: 10.1164/rccm.201604-0700OC.
doi: 10.1164/rccm.201604-0700OC URL |
[17] |
Mougari F, Amarsy R, Veziris N, et al. Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother, 2016, 71(8):2208-2212. doi: 10.1093/jac/dkw130.
doi: 10.1093/jac/dkw130 pmid: 27147307 |
[18] |
Lee SH, Yoo HK, Kim SH, et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med, 2014, 34(1):31-37. doi: 10.3343/alm.2014.34.1.31.
doi: 10.3343/alm.2014.34.1.31 URL |
[19] |
Garcia de Carvalho NF, Sato DN, Pavan FR, er al. Resazurin Microtiter Assay for clrrithromycin Susceptibility Testing of Clinical Isolates of Mycobacterium abscessus Group. J Clin Lab Anal, 2016, 30(5):751-755. doi: 10.1002/jcla.21933.
doi: 10.1002/jcla.21933 URL |
[20] |
Guo Q, Wei J, Zou W, et al. Antimicrobial susceptibility profiles of Mycobacterium abscessus complex isolates from respiratory specimens in Shanghai, China. J Glob Antimicrob Resist, 2021, 25:72-76. doi: 10.1016/j.jgar.2021.02.024.
doi: 10.1016/j.jgar.2021.02.024 URL |
[1] | Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 859-866. |
[2] | ZHOU Wen-qiang, ZHANG Shuang, CHU Nai-hui. Current status and prospect of all-oral treatment regimens for drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 879-882. |
[3] | DING Cai-hong, XIONG Yu, WANG Qing, GAO Xu-sheng, HAO Yan. Study on the early efficacy and safety of the regimen containing bedaquiline in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 893-898. |
[4] | WU Guo-lan, GAO Jing-tao, CHEN Xiao-hong, CHEN Li-zhou, WENG Li-zhen, GUO Zhi-ping, CHEN Xiu-ping, LIN Jian-dong, CHEN Su-xia, GAO Meng-qiu, LIU Yu-hong. Short-term effectiveness and safety of a regimen containing bedaquiline in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 899-904. |
[5] | SHI Wen-hui, CHU Nai-hui. Resistance to fluoroquinolones and the influencing factors in patients with drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 905-909. |
[6] | LIN Jian, LIN Shu-fang, DAI Zhi-song, ZHAO Yong, ZHOU Yin-fa, ZHANG Tian-lin, WEI Shu-zhen. Analysis of the drug resistance surveillance results of Mycobacterium tuberculosis in Fujian Province from 2016 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 924-928. |
[7] | YU Xia, REN Ru-yan, WEN Shu-an, LIANG Qian, DONG Ling-ling, HUANG Hai-rong. Evaluation of in vitro antibacterial effects of 13 antibiotics against rapidly growing mycobacteria [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 947-951. |
[8] | MA Ting-ting, REN Fei, MA Jin-bao, YANG Han. Resistance of prothionamided and sodium aminosalicylate among isoniazid resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 961-964. |
[9] | XIA Hui, ZHAO Yan-lin. Inspiration of the WHO Updated on the use of nucleic acid amplification tests to detect TB and drug-resistant TB: rapid communication [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 761-765. |
[10] | HU Yan-jie, GONG Shi-wei, REN Yi. Establishment and evaluation of rapid detection of pyrazinamide resistance of Mycobacterium tuberculosis by probe enzyme digestion using Surveyor [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 813-816. |
[11] | YANG Ting-ting, GAO Qian. The tuberculosis drug-resistance and transmission surveillance network based on whole genome sequencing data [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 645-648. |
[12] | YI Jun-li, YANG Xin-yu, CHEN Hao, ZHAO Yan-feng, CHEN Shuang-shuang, ZHANG Jie, DING Bei-chuan, DAI Xiao-wei, SUN Shan-hua, WU Wen-qing, LI Chuan-you. Analysis of drug resistance of 1156 clinical isolates of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 677-681. |
[13] | CAO Pan, LIANG Kuang-li, YUAN Ji-xin, LI Yong-bo, CHEN Rui, ZHANG Zhi-fei, WU Qian-hong. Analysis of CT findings in patients with initial and retreated cavernous rifampicin-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 694-701. |
[14] | YAO Rong, LU Yu. Research and progress of early bactericidal activity of anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 724-728. |
[15] | CHANG Jun-li, ZHANG Jian-hong, ZHANG Ying, ZHANG Hai-fang, FAN Peng-fei, LI Qiu-hua, DING Xue-ling. Investigation and analysis of a cluster epidemic of rifampicin-resistant tuberculosis in a school [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 751-754. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||